Examples are the CBFA2T3-GLIS2 fusion (acute megakaryoblastic leukemia, FAB M7)35,36 and the five druggable events (depending on clinical trials or compassionate use): ZCCHC8-ROS1 (high-grade glioma), PPP1CB-ALK (high-grade glioma), EML4-ALK (papillary thyroid carcinoma), FGFR2-VCL (embryonal rhabdomyosarcoma), and EML4-NTRK3 (IF). This evidence concerns the gene FGFR2 and embryonal rhabdomyosarcoma.